Health Care • Medicinal Chemicals and Botanical Products
$7.91 ▼ -0.39
(-4.70%)
MKT CAP: $74.3M • VOL: 21.8K
52W L $8 52W H $20
FTLF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $15.9M | $64.5M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $6.9M | $28.1M | — |
| Gross Margin % | 43.1% | 43.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $3.0M | $13.1M | $7.5M |
| Operating Margin % | 18.6% | 20.3% | — |
| Net Income (GAAP) | $6.3M | $9.0M | $5.3M |
| EBITDA (Normalized) | $3.0M | $13.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $7.4M | $9.6M | $4.2M |
| Capital Expenditures (CapEx) | $42.0K | $10.0K | — |
| Free Cash Flow (FCF) | $7.4M | $9.6M | $4.2M |
| FCF Margin % | 46.4% | 14.9% | — |
| Return on Invested Capital (ROIC %) | 5.4% | 23.2% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | $8.6M | — |
| Total Stockholders' Equity | $43.6M | $36.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FTLF.